Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2020

Open Access 01-12-2020 | Magnetic Resonance Imaging | Case report

A case report of thyroid-associated Orbitopathy with elevated TPO antibodies

Authors: Radwan El Othman, Christelle Ephrem, Elsie Touma, Souheil Hallit, Rola El Othman

Published in: BMC Endocrine Disorders | Issue 1/2020

Login to get access

Abstract

Background

Thyroid associated orbitopathy (TAO) is defined as an immune mediated inflammatory process affecting the extraocular muscles, connective and adipose tissue of uncertain etiopathogenesis. TAO are classically described in Grave’s disease (GD) however it may occur in euthyroid and hypothyroid patients. Those patients usually test positive for Thyroid Stimulating Hormone receptor antibodies (TRAb). For instance, only few cases of severe Hashimoto’s thyroiditis (HT) associated orbitopathy with negative TRAb are reported to date.

Case presentation

Herewith we report a rare case of a middle-aged female who presented with bilateral progressive upper and lower palpebral edema and a unilateral marked proptosis associated with asthenia, headache and decrease in visual acuity. Biological investigation was notable for high levels of anti-thyroid peroxidase antibodies (Anti-TPO) in an otherwise euthyroid patient with negative TRAb. Orbital Magnetic resonance imaging revealed edema of the extraocular muscles and inflammation of periorbital soft tissue. The patient received a treatment with intravenous methylprednisolone followed by oral treatment with prednisone. This regimen was both effective and safe with minimal metabolic side effects in our patient.

Conclusion

Minor ocular manifestations of HT are common; however, severe sight threatening ophtalmopathy in the absence of TRAb is rare. Multiple differential diagnosis should be considered and investigated before diagnosing this rare entity. Management of similar cases is currently based on reports and no clear guidelines have been elaborated, corticosteroids is the mainstream of treatment with a potential benefit of selenium supplementation in mild to moderate cases.
Literature
1.
go back to reference Yoshihara A, Yoshimura Noh J, Nakachi A, et al. Severe thyroidassociated orbitopathy in Hashimoto’s thyroiditis. Report of 2 cases. Endocr J. 2011;58:343–8..CrossRef Yoshihara A, Yoshimura Noh J, Nakachi A, et al. Severe thyroidassociated orbitopathy in Hashimoto’s thyroiditis. Report of 2 cases. Endocr J. 2011;58:343–8..CrossRef
5.
go back to reference Mengistu M, Lukes YG, Nagy EV, Burch HB, Carr FE, Lahiri S, et al. TSH receptor gene expression in retroocular fibroblasts. J Endocrinol Investig. 1994;17(6):437–41..CrossRef Mengistu M, Lukes YG, Nagy EV, Burch HB, Carr FE, Lahiri S, et al. TSH receptor gene expression in retroocular fibroblasts. J Endocrinol Investig. 1994;17(6):437–41..CrossRef
6.
go back to reference Paschke R, Metcalfe A, Alcalde L, Vassart G, Weetman A, Ludgate M. Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissues. J Clin Endocrinol Metab. 1994;79(5):1234–8.PubMed Paschke R, Metcalfe A, Alcalde L, Vassart G, Weetman A, Ludgate M. Presence of nonfunctional thyrotropin receptor variant transcripts in retroocular and other tissues. J Clin Endocrinol Metab. 1994;79(5):1234–8.PubMed
7.
go back to reference Iyer S, Bahn R. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab. 2012;26(3):281–9.CrossRef Iyer S, Bahn R. Immunopathogenesis of Graves' ophthalmopathy: the role of the TSH receptor. Best Pract Res Clin Endocrinol Metab. 2012;26(3):281–9.CrossRef
8.
go back to reference Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177–85.CrossRef Shan SJ, Douglas RS. The pathophysiology of thyroid eye disease. J Neuroophthalmol. 2014;34(2):177–85.CrossRef
9.
go back to reference Lahooti H, Parmar KR, Wall JR. Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role? Clin Ophthalmol. 2010;4:417–25.PubMedPubMedCentral Lahooti H, Parmar KR, Wall JR. Pathogenesis of thyroid-associated ophthalmopathy: does autoimmunity against calsequestrin and collagen XIII play a role? Clin Ophthalmol. 2010;4:417–25.PubMedPubMedCentral
10.
go back to reference Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, Konig J. Thyroid stimulating antibodies are highly prevalent in Hashimoto's thyroiditis and associated Orbitopathy. J Clin Endocrinol Metab. 2016;101(5):1998–2004.CrossRef Kahaly GJ, Diana T, Glang J, Kanitz M, Pitz S, Konig J. Thyroid stimulating antibodies are highly prevalent in Hashimoto's thyroiditis and associated Orbitopathy. J Clin Endocrinol Metab. 2016;101(5):1998–2004.CrossRef
11.
go back to reference Bozkurt NC, Karbek B, Ucan B, Sahin M, Cakal E, Ozbek M, et al. The association between severity of vitamin D deficiency and Hashimoto's thyroiditis. Endocr Pract. 2013;19(3):479–84.CrossRef Bozkurt NC, Karbek B, Ucan B, Sahin M, Cakal E, Ozbek M, et al. The association between severity of vitamin D deficiency and Hashimoto's thyroiditis. Endocr Pract. 2013;19(3):479–84.CrossRef
12.
go back to reference Kim D. Low vitamin D status is associated with hypothyroid Hashimoto's thyroiditis. Hormones (Athens). 2016;15(3):385–93. Kim D. Low vitamin D status is associated with hypothyroid Hashimoto's thyroiditis. Hormones (Athens). 2016;15(3):385–93.
13.
go back to reference Mansournia N, Mansournia MA, Saeedi S, Dehghan J. The association between serum 25OHD levels and hypothyroid Hashimoto's thyroiditis. J Endocrinol Investig. 2014;37(5):473–6.CrossRef Mansournia N, Mansournia MA, Saeedi S, Dehghan J. The association between serum 25OHD levels and hypothyroid Hashimoto's thyroiditis. J Endocrinol Investig. 2014;37(5):473–6.CrossRef
14.
go back to reference Lahooti H, Edirimanne S, Walsh JP, Delbridge L, Hibbert EJ, Wall JR. Single nucleotide polymorphism 1623 a/G (rs180195) in the promoter of the thyroglobulin gene is associated with autoimmune thyroid disease but not with thyroid ophthalmopathy. Clin Ophthalmol. 2017;11:1337–45.CrossRef Lahooti H, Edirimanne S, Walsh JP, Delbridge L, Hibbert EJ, Wall JR. Single nucleotide polymorphism 1623 a/G (rs180195) in the promoter of the thyroglobulin gene is associated with autoimmune thyroid disease but not with thyroid ophthalmopathy. Clin Ophthalmol. 2017;11:1337–45.CrossRef
15.
go back to reference Boddu N, Jumani M, Wadhwa V, Bajaj G, Faas F. Not all Orbitopathy is Graves': discussion of cases and review of literature. Front Endocrinol (Lausanne). 2017;8:184.CrossRef Boddu N, Jumani M, Wadhwa V, Bajaj G, Faas F. Not all Orbitopathy is Graves': discussion of cases and review of literature. Front Endocrinol (Lausanne). 2017;8:184.CrossRef
16.
go back to reference McNab AA, McKelvie P. IgG4-related ophthalmic disease. Part II: clinical aspects. Ophthalmic Plast Reconstr Surg. 2015;31(3):167–78.CrossRef McNab AA, McKelvie P. IgG4-related ophthalmic disease. Part II: clinical aspects. Ophthalmic Plast Reconstr Surg. 2015;31(3):167–78.CrossRef
17.
go back to reference Ruchala M, Szczepanek E, Puszczewicz M, Sosnowski P, Sowinski J. Not a graves' situation. Am J Med. 2011;124(3):210–4.CrossRef Ruchala M, Szczepanek E, Puszczewicz M, Sosnowski P, Sowinski J. Not a graves' situation. Am J Med. 2011;124(3):210–4.CrossRef
18.
go back to reference Kahaly GJ. Imaging in thyroid-associated orbitopathy. Eur J Endocrinol. 2001;145(2):107–18.CrossRef Kahaly GJ. Imaging in thyroid-associated orbitopathy. Eur J Endocrinol. 2001;145(2):107–18.CrossRef
19.
go back to reference Tjiang H, Lahooti H, McCorquodale T, Parmar KR, Wall JR. Eye and eyelid abnormalities are common in patients with Hashimoto's thyroiditis. Thyroid. 2010;20(3):287–90.CrossRef Tjiang H, Lahooti H, McCorquodale T, Parmar KR, Wall JR. Eye and eyelid abnormalities are common in patients with Hashimoto's thyroiditis. Thyroid. 2010;20(3):287–90.CrossRef
20.
go back to reference Kan E, Kan EK, Ecemis G, Colak R. Presence of thyroid-associated ophthalmopathy in Hashimoto's thyroiditis. Int J Ophthalmol. 2014;7(4):644–7.PubMedPubMedCentral Kan E, Kan EK, Ecemis G, Colak R. Presence of thyroid-associated ophthalmopathy in Hashimoto's thyroiditis. Int J Ophthalmol. 2014;7(4):644–7.PubMedPubMedCentral
21.
go back to reference Grzesiuk W, Szydlarska D, Pragacz A, Bar-Andziak E. Thyroid-associated orbitopathy in patients with Hashimoto's thyroiditis: a case report. Pol Arch Med Wewn. 2008;118(5):318–21.PubMed Grzesiuk W, Szydlarska D, Pragacz A, Bar-Andziak E. Thyroid-associated orbitopathy in patients with Hashimoto's thyroiditis: a case report. Pol Arch Med Wewn. 2008;118(5):318–21.PubMed
22.
go back to reference Kirmizibekmez H, Yesiltepe Mutlu RG. Atypical presentation of Hashimoto's disease in an adolescent: thyroid-associated Ophthalmopathy. J Clin Res Pediatr Endocrinol. 2014;6(4):262–5.CrossRef Kirmizibekmez H, Yesiltepe Mutlu RG. Atypical presentation of Hashimoto's disease in an adolescent: thyroid-associated Ophthalmopathy. J Clin Res Pediatr Endocrinol. 2014;6(4):262–5.CrossRef
24.
go back to reference Ruchala M, Sawicka-Gutaj N. Advances in the pharmacological treatment of Graves' orbitopathy. Expert Rev Clin Pharmacol. 2016;9(7):981–9.CrossRef Ruchala M, Sawicka-Gutaj N. Advances in the pharmacological treatment of Graves' orbitopathy. Expert Rev Clin Pharmacol. 2016;9(7):981–9.CrossRef
25.
go back to reference Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European thyroid association/European group on Graves' Orbitopathy guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016;5(1):9–26.CrossRef Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, et al. The 2016 European thyroid association/European group on Graves' Orbitopathy guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016;5(1):9–26.CrossRef
26.
go back to reference Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320–32.CrossRef Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves' orbitopathy: efficacy and morbidity. J Clin Endocrinol Metab. 2011;96(2):320–32.CrossRef
27.
go back to reference Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly G. J, Marcocci C, Perros P, Salvi M, Wiersinga W, M: the 2016 European thyroid association/European group on Graves' Orbitopathy guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016;5:9–26.CrossRef Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly G. J, Marcocci C, Perros P, Salvi M, Wiersinga W, M: the 2016 European thyroid association/European group on Graves' Orbitopathy guidelines for the Management of Graves' Orbitopathy. Eur Thyroid J. 2016;5:9–26.CrossRef
28.
go back to reference Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol. 2013;78(2):155–64.CrossRef Drutel A, Archambeaud F, Caron P. Selenium and the thyroid gland: more good news for clinicians. Clin Endocrinol. 2013;78(2):155–64.CrossRef
Metadata
Title
A case report of thyroid-associated Orbitopathy with elevated TPO antibodies
Authors
Radwan El Othman
Christelle Ephrem
Elsie Touma
Souheil Hallit
Rola El Othman
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2020
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-020-00658-6

Other articles of this Issue 1/2020

BMC Endocrine Disorders 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.